May 31, 2019 Clinical Research/Diagn. Product Launch

Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care

Basel, 31 May 2019 Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care Radiologists can now upload their patient records to the same dashboard as patient files from other disciplines First collaboration product enables tumour boards to have a more comprehensive view of... Read more

May 30, 2019 Clinical Research/Diagn. M&A, Partnerships

NanoString Partners with Multiple Leading Contract Research Organizations to Provide Standardized PanCancer IO 360 Data Analysis Reports

Program Extends Ability of CAP CLIA Labs to Develop a Tumor Inflammation Signature Assay to Support Translational Research by Biopharmaceutical Companies SEATTLE, May 30, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced commercial partnerships with three Contract Research Organizations (CROs), including Covance, NeoGenomics Laboratories,... Read more

May 29, 2019 Clinical Research/Diagn.

Quanterix Expands Headquarters to New, State-of-the-art Facility in Billerica, Mass. As Demand Continues to Grow for Its Disruptive Simoa Platforms

MAY 29, 2019 World-class facility will offer the Company nearly three times the space for disruptive biomarker technology innovation and to accommodate growing pharma services business Billerica, Mass. – May 29, 2019 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters... Read more

May 28, 2019 Clinical Research/Diagn. Product Launch

Roche launches first in vitro diagnostic IHC test to detect ROS1 protein in cancers

VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody IHC staining of lung adenocarcinoma tissue Roche’s VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market The biomarker may provide a cost-effective and efficient means to initially identify elevated ROS1 protein expression in cancer ROS1-positive cancer... Read more

May 24, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Product Launch

QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer

Germantown, Maryland, and Hilden, Germany, May 24, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the immediate launch of its therascreen® PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY (alpelisib), a... Read more

May 21, 2019 Clinical Research/Diagn. PR/Corporate

QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

Hilden, Germany and Germantown, Maryland, May 21, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the Joint United Nations Programme on HIV/AIDS... Read more

May 18, 2019 Clinical Research/Diagn. Lab Top-10 Product Launch

New State-of-the-Art Facility Increases Agilent's Capacity to Produce Nucleic Acid-Based Therapeutics

New State-of-the-Art Facility Increases Agilent’s Capacity to Produce Nucleic Acid-Based Therapeutics New facility in Frederick, Colorado, to produce high-quality molecules with the potential to treat cancer and other diseases SANTA CLARA, Calif., June 18, 2019 Agilent Technologies Inc. (NYSE: A) today announced the opening of a production facility in Colorado that more than doubles its... Read more

May 16, 2019 Clinical Research/Diagn.

QIAGEN and Inovio collaborate to develop companion diagnostic for novel immunotherapy targeting precancerous cervical lesions

Hilden, Germany, Germantown, Maryland, and Plymouth Meeting, Pennsylvania, May 16, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Inovio Pharmaceuticals Inc. (NASDAQ: INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV).... Read more

May 15, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Lab Top-10 Product Launch

New Study Demonstrates Clinical Utility of Liquid Biopsy for Cancer Monitoring

Multi-institutional clinical research indicates liquid biopsy can detect changes in tumor profile and resistance to treatment CARLSBAD, Calif., May 15, 2019 /PRNewswire/ — Growing scientific evidence supports liquid biopsy as a valuable tool for monitoring treatment response in patients with cancer. A new retrospective clinical research study showing comparable results between liquid and tissue biopsy in... Read more

May 15, 2019 Clinical Research/Diagn. Liq. Handling & Robotics

GE Healthcare announces commercial launch of Chronicle™ automation software for cell therapy

May 15, 2019 – GE Healthcare builds on its digital capabilities with the Chronicle web application, the next generation development of my.Cryochain™ software now supporting the complete cell therapy workflow. Chronicle automation software is a GMP compliant fit-for-purpose digital solution designed to optimize complex cell therapy process development and manufacturing. With real-time supply chain tracking,... Read more